Back to today’s briefing

Story perspectives

GLP-1 Medications Linked to Lower Dry AMD Risk

10/29/2025

50 12

Summary

Story summary

Researchers report that Wegovy and Saxenda, glucagon-like peptide-1 medications, are associated with a lower risk of dry AMD in adults without diabetes.
The risk drops 84% after five years and 91% after ten years.
Researchers caution the findings show association, not causation, and call for randomized trials.
The study notes effects on wet AMD are unclear, and experts urge caution before using GLP-1s for eye protection amid rising obesity.

1 of 1

Story summary

Researchers report that Wegovy and Saxenda, glucagon-like peptide-1 medications, are associated with a lower risk of dry AMD in adults without diabetes.
The risk drops 84% after five years and 91% after ten years.
Researchers caution the findings show association, not causation, and call for randomized trials.
The study notes effects on wet AMD are unclear, and experts urge caution before using GLP-1s for eye protection amid rising obesity.